Hematological Diseases Therapy Landscape Canvassed by GBI Research in Its Topical Report Published at MarketPublishers.com

25 Sep 2017 • by Natalie Aster

LONDON – The hematological diseases therapy area comprises benign disorders of the blood like anemia, sickemia, agranulocytosis and hemophilia. Amid the three disease categories, red blood cell disorders are characterised by high unmet needs pertaining to few efficient treatment modalities and dismal prognosis.

Initially, the blood disorders therapy field area has been adversely impacted by a dearth of financing of research, which has increased the degree of unmet need, though there have been cases in which financing of an indication has led to a strong RoI. A prominent example is the approval of Soliris as of 2007, which is utilised for the treatment of the orphan disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is one of the 2 marketed treatments for PNH, and is projected to reach over USD 3 billion in annual revenue by 2017-end, reaching USD 5.5 billion by end-2023.

There are 92 first-in-class drugs in the pipeline in this therapy field; accounting for 28% of products in total pipeline for which there is a disclosed molecular target, and act on 71 one-of-a-kind individual molecular targets.

Topical report “Frontier Pharma: Hematological Disorders” drawn up by GBI Research gives a trustworthy, all-round assessment of first-in-class innovation in the pipeline  of hematological disorder drugs, limelighting major trends in the pipeline, and also emerging classes of treatment.

The study discusses the present-day commercial and clinical landscape, including an extensive analysis of disorder pathogenesis, diagnosis and prognosis, and the actual treatment modalities. The report examines the structure of the blood disorders market with respect to main molecule targets and types, limelighting the actual unmet needs and how they can be dealt with. It reviews the blood disorders pipeline, stratifying it by development stage, molecule type and molecular target. The report evaluates the therapeutic prospects of first-in-class targets, focusing on early-stage targets that hold great promise. The research casts light on the opportunities in the pertinent deals landscape.

Find many other topical market studies by the publisher in the GBI Research catalogue at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com